SUPPLEMENTAL TABLE 1. Multivariate logistic regression models for failure to achieve CR, without inclusion of NPM1 and FLT3-ITD mutational information

Parameter / MRC/NCRI
n = 2,615 / HOVON/SAKK
n = 1,134 / SWOG
n = 443 / MDA
n = 409 / All
n = 4,601
Age (per 1 year) / 1.06 (1.05-1.07), P<0.001 / 1.01 (0.99-1.02), P=0.43 / 1.01 (1.00-1.03), P=0.086 / 1.03 (1.01-1.05), P=0.0026 / 1.04 (1.04-1.05), P<0.001
Performance status
0-1
2-4 / 1.00 (reference)
1.50 (1.12-2.00), P=0.0061 / 1.00 (reference)
1.36 (0.74-2.52), P=0.32 / 1.00 (reference)
1.11 (0.63-1.96), P=0.72 / 1.00 (reference)
0.88 (0.39-1.99), P=0.76 / 1.00 (reference)
1.27 (1.02-1.58), P=0.036
WBC (per 10,000/µL) / 1.20 (0.98-1.47), P=0.0073 / 1.91 (1.42-2.56), P<0.001 / 1.67(1.07-2.60), P=0.024 / 1.85(0.88-3.86), P=0.10 / 1.32(1.15-1.52), P<0.001
Platelets (per 10,000/µL) / 1.15(1.02-1.30), P=0.024 / 1.30 (1.13-1.50), P<0.001 / 0.97 (0.89-1.05), P=0.46 / 1.17(0.88-1.55), P=0.29 / 1.02(0.98-1.05), P=0.32
BM blasts (per 10%) / 0.99 (0.95-1.41), P=0.68 / 0.96(0.90-1.03), P=0.24 / 0.96 (0.87-1.05), P=0.39 / 0.92(0.83-1.02), P=0.14 / 0.97 (0.95-1.01), P=0.11
Gender
Female
Male / 1.00 (reference)
1.13 (0.91-1.41), P=0.28 / 1.00 (reference)
1.20 (0.86-1.69), P=0.29 / 1.00 (reference)
0.85 (0.56-1.31), P=0.47 / 1.00 (reference)
1.38 (0.87-2.19), P=0.18 / 1.00 (reference)
1.14 (0.98-1.34), P=0.09
Type of AML
De novo (primary)
Secondary / 1.00 (reference)
3.22 (2.46-4.23), P<0.001 / 1.00 (reference)
1.72 (1.03-2.88), P=0.038 / 1.00 (reference)
2.97 (1.03-8.59), P=0.044 / 1.00 (reference)
1.59 (1.00-2.54), P=0.052 / 1.00 (reference)
2.38 (1.96-2.88), P<0.001
Cytogenetics
Favorable
Intermediate
Unfavorable / 0.18 (0.07-0.44), P<0.001
1.00 (reference)
4.61 (3.37-6.32), P<0.001 / 0.49 (0.23-1.05), P=0.07
1.00 (reference)
3.32 (2.31-4.78), P<0.001 / 0.33 (0.14-0.75), P=0.0078
1.00 (reference)
2.54 (1.51-4.29), P<0.001 / 0.21 (0.06-0.70), P=0.011
1.00 (reference)
2.52 (1.55-4.08), P<0.001 / 0.31 (0.20-0.47), P<0.001
1.00 (reference)
3.45 (2.86-4.17), P<0.001
Bootstrap-corrected AUC / 0.81 / 0.71 / 0.66 / 0.72 / 0.76

Data is presented as odds ratio (95% CI). The model also contained a covariate “missing cytogenetics”.

Abbreviations:BM, bone marrow; CR, complete remission; WBC, white blood cells.

SUPPLEMENTAL TABLE 2. Multivariate logistic regression models for failure to achieve CR or RFS ≤3 months, without inclusion of NPM1 and FLT3-ITD mutational information

Parameter / MRC/NCRI
n = 2,573 / HOVON/SAKK
n = 1,134 / SWOG
n = 443 / MDA
n = 402 / All
n = 4,552
Age (per 1 year) / 1.05 (1.04-1.06), P<0.001 / 1.01 (1.00-1.03), P=0.028 / 1.02 (1.00-1.03), P=0.032 / 1.02 (1.01-1.04), P=0.0069 / 1.04 (1.03-1.04), P<0.001
Performance status
0-1
2-4 / 1.00 (reference)
1.29 (1.00-1.66), P=0.05 / 1.00 (reference)
0.84 (0.48-1.49), P=0.56 / 1.00 (reference)
1.22 (0.70-2.15), P=0.48 / 1.00 (reference)
2.28 (1.02-5.09), P=0.044 / 1.00 (reference)
1.19 (0.97-1.44), P=0.09
WBC (per 10,000/µL) / 1.37(1.15-1.62), P<0.001 / 1.90(1.46-2.47), P<0.001 / 1.59(1.03-2.47), P=0.038 / 2.22 (1.01-4.88), P=0.048 / 1.45(1.28-1.66), P<0.001
Platelets (per 10,000/µL) / 1.13(1.01-1.27), P=0.031 / 1.16(1.01-1.33), P=0.029 / 1.01(0.98-1.04), P=0.58 / 1.15(0.87-1.52), P=0.33 / 1.04(0.99-1.08), P=0.10
BM blasts (per 10%) / 0.97 (0.93-1.01), P=0.09 / 0.97(0.91-1.02), P=0.26 / 0.98 (0.89-1.07), P=0.60 / 0.96 (0.87-1.06), P=0.43 / 0.97 (0.94-0.99), P=0.022
Gender
Female
Male / 1.00 (reference)
1.06 (0.87-1.29), P=0.57 / 1.00 (reference)
1.14 (0.86-1.52), P=0.37 / 1.00 (reference)
0.88 (0.58-1.34), P=0.56 / 1.00 (reference)
1.50 (0.96-2.34), P=0.073 / 1.00 (reference)
1.11 (0.97-1.28), P=0.14
Type of AML
De novo (primary)
Secondary / 1.00 (reference)
3.03 (2.32-3.95), P<0.001 / 1.00 (reference)
1.81 (1.15-2.83), P=0.010 / 1.00 (reference)
3.09 (1.02-9.33), P=0.046 / 1.00 (reference)
1.50 (0.96-2.35), P=0.077 / 1.00 (reference)
2.30 (1.91-2.77), P<0.001
Cytogenetics
Favorable
Intermediate
Unfavorable / 0.43 (0.26-0.71), P=0.0011
1.00 (reference)
4.20 (3.12-5.65), P<0.001 / 0.84 (0.51-1.41), P=0.52
1.00 (reference)
3.00 (2.24-4.25), P<0.001 / 0.29 (0.13-0.65), P=0.0027
1.00 (reference)
2.96 (1.75-4.99), P<0.001 / 0.20 (0.07-0.61), P=0.0045
1.00 (reference)
2.42 (1.52-3.87), P<0.001 / 0.48 (0.35-0.65), P<0.001
1.00 (reference)
3.40 (2.85-4.07), P<0.001
Bootstrap-corrected AUC / 0.78 / 0.68 / 0.69 / 0.72 / 0.74

Data is presented as odds ratio (95% CI). The model also contained a covariate “missing cytogenetics”.

Abbreviations:BM, bone marrow; CR, complete remission; WBC, white blood cells.

SUPPLEMENTAL TABLE 3. Multivariate logistic regression models for failure to achieve CR or RFS ≤6 months, without inclusion of NPM1 and FLT3-ITD mutational information

Parameter / MRC/NCRI
n = 2,544 / HOVON/SAKK
n = 1,130 / SWOG
n = 441 / MDA
n = 388 / All
n = 4,503
Age (per 1 year) / 1.04 (1.03-1.05), P<0.001 / 1.01 (1.00-1.03), P=0.001 / 1.03 (1.01-1.04), P=0.0014 / 1.02 (1.00-1.04), P=0.023 / 1.03 (1.03-1.04), P<0.001
Performance status
0-1
2-4 / 1.00 (reference)
1.14 (0.91-1.43), P=0.26 / 1.00 (reference)
0.87 (0.52-1.44), P=0.60 / 1.00 (reference)
1.45 (0.82-2.54), P=0.20 / 1.00 (reference)
2.89 (1.18-7.09), P=0.02 / 1.00 (reference)
1.17 (0.97-1.40), P=0.10
WBC (per 10,000/µL) / 1.52(1.29-1.79), P<0.001 / 2.08(1.61-2.68), P<0.001 / 1.69(1.07-2.68), P=0.025 / 4.94 (1.78-13.7), P=0.0021 / 1.64(1.44-1.86), P<0.001
Platelets (per 10,000/µL) / 1.10 (0.99-1.22), P=0.09 / 1.01(0.89-1.14), P=0.85 / 1.01(0.97-1.04), P=0.71 / 1.09(0.82-1.45), P=0.54 / 1.02(0.98-1.05), P=0.35
BM blasts (per 10%) / 0.97 (0.93-1.00), P=0.064 / 0.99 (0.93-1.04), P=0.60 / 1.01(0.92-1.11), P=0.87 / 0.90(0.81-0.99), P=0.036 / 0.97 (0.94-0.99), P=0.030
Gender
Female
Male / 1.00 (reference)
1.04 (0.87-1.24), P=0.69 / 1.00 (reference)
1.13 (0.87-1.46), P=0.37 / 1.00 (reference)
0.89 (0.59-1.34), P=0.57 / 1.00 (reference)
1.32 (0.84-2.06), P=0.22 / 1.00 (reference)
1.08 (0.95-1.24), P=0.23
Type of AML
De novo (primary)
Secondary / 1.00 (reference)
2.59 (1.97-3.41), P<0.001 / 1.00 (reference)
1.44 (0.93-2.25), P=0.11 / 1.00 (reference)
3.79 (1.08-13.32), P=0.037 / 1.00 (reference)
1.36 (0.86-2.13), P=0.18 / 1.00 (reference)
2.00 (1.66-2.41), P<0.001
Cytogenetics
Favorable
Intermediate
Unfavorable / 0.41 (0.28-0.61), P<0.001
1.00 (reference)
5.18 (3.81-7.03), P<0.001 / 0.66 (0.42-1.05), P=0.08
1.00 (reference)
3.49 (2.57-4.73), P<0.001 / 0.23 (0.11-0.52), P<0.001
1.00 (reference)
2.96 (1.73-5.08), P<0.001 / 0.12 (0.04-0.35), P<0.001
1.00 (reference)
2.17 (1.35-3.49), P=0.0014 / 0.41 (0.31-0.53), P<0.001
1.00 (reference)
3.71 (3.10-4.43), P<0.001
Bootstrap-corrected AUC / 0.76 / 0.69 / 0.72 / 0.72 / 0.73

Data is presented as odds ratio (95% CI). The model also contained a covariate “missing cytogenetics”.

Abbreviations:BM, bone marrow; CR, complete remission; WBC, white blood cells.

SUPPLEMENTAL TABLE 4. Multivariate logistic regression models for failure to achieve CR or RFS ≤12 months, without inclusion of NPM1 and FLT3-ITD mutational information

Parameter / MRC/NCRI
n = 2,523 / HOVON/SAKK
n = 1,124 / SWOG
n = 439 / MDA
n = 371 / All
n = 4,457
Age (per 1 year) / 1.04 (1.03-1.04), P<0.001 / 1.01 (0.99-1.02), P=0.31 / 1.02 (1.01-1.04), P=0.0037 / 1.03 (1.01-1.04), P=0.0063 / 1.03 (1.03-1.03), P<0.001
Performance status
0-1
2-4 / 1.00 (reference)
1.13 (0.91-1.40), P=0.28 / 1.00 (reference)
0.73 (0.45-1.20), P=0.21 / 1.00 (reference)
1.36 (0.77-2.40), P=0.29 / 1.00 (reference)
2.04 (0.75-5.54), P=0.16 / 1.00 (reference)
1.13 (0.94-1.34), P=0.19
WBC (per 10,000/µL) / 1.46(1.24-1.73), P<0.001 / 2.05 (1.58-2.65), P<0.001 / 2.60 (1.46-4.62), P=0.0012 / 6.68 (1.73-25.8), P=0.0058 / 1.64(1.44-1.88), P<0.001
Platelets (per 10,000/µL) / 0.98 (0.88-1.09), P=0.71 / 1.05(0.92-1.20), P=0.39 / 1.00 (0.96-1.03), P=0.82 / 0.97 (0.73-1.30), P=0.84 / 1.00 (0.97-1.03), P=0.90
BM blasts (per 10%) / 0.97 (0.93-1.00), P=0.089 / 0.98 (0.93-1.03), P=0.39 / 1.01(0.92-1.11), P=0.80 / 0.94(0.84-1.04), P=0.22 / 0.98 (0.95-1.00), P=0.10
Gender
Female
Male / 1.00 (reference)
1.15 (0.96-1.36), P=0.13 / 1.00 (reference)
1.03 (0.80-2.37), P=0.81 / 1.00 (reference)
0.91 (0.60-1.37), P=0.65 / 1.00 (reference)
1.26 (0.78-2.04), P=0.34 / 1.00 (reference)
1.12 (0.98-1.27), P=0.09
Type of AML
De novo (primary)
Secondary / 1.00 (reference)
2.16 (1.58-2.96), P<0.001 / 1.00 (reference)
1.50 (0.95-2.37), P=0.09 / 1.00 (reference)
2.73 (0.72-10.36), P=0.14 / 1.00 (reference)
1.11 (0.69-1.80), P=0.67 / 1.00 (reference)
1.70 (1.39-2.08), P<0.001
Cytogenetics
Favorable
Intermediate
Unfavorable / 0.54 (0.40-0.73), P<0.001
1.00 (reference)
5.24 (3.61-7.61), P<0.001 / 0.67 (0.36-0.99), P=0.046
1.00 (reference)
3.42 (2.49-4.70), P<0.001 / 0.46 (0.25-0.86), P=0.014
1.00 (reference)
2.50 (1.41-4.44), P=0.0017 / 0.12 (0.05-0.29), P<0.001
1.00 (reference)
2.27 (1.34-3.85), P=0.0023 / 0.53 (0.43-0.65), P<0.001
1.00 (reference)
3.48 (2.86-4.24), P<0.001
Bootstrap-corrected AUC / 0.73 / 0.68 / 0.69 / 0.72 / 0.71

Data is presented as odds ratio (95% CI). The model also contained a covariate “missing cytogenetics”.

Abbreviations:BM, bone marrow; CR, complete remission; WBC, white blood cells.

1